BEATHealthcare · Health Information ServicesThe 3 Wall Street analysts covering HeartBeam, Inc. hold a median 12-month price target of $3.5 — +725.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores HeartBeam, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BEAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +725.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 July 2026 | Maxim Group | Initiates | Buy | $2.00 |
| 14 July 2026 | Maxim Group | Initiates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | $5.50 → $2.50 |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | — |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | $8.00 → $5.00 |
| 31 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 30 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | D. Boral Capital | Initiates | Buy | — |
| 16 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2025 | Benchmark | Upgrade | Buy | — |
| 10 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 4 Sept 2024 | Benchmark | Reiterates | Speculative Buy | $8.00 |
| 13 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 25 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 16 Nov 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 24 Aug 2023 | Benchmark | Reiterates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BEAT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, HeartBeam, Inc. returned −74.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 31% of US stocks
Cheaper than 68% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 5% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HeartBeam, Inc. has a market value of $23.0M and an enterprise value of $14.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.3M.
Free cash flow in the twelve months to 30 June 2026: −$14.0M.
Trailing P/E: −0.7×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
HeartBeam, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HeartBeam, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
HeartBeam announced it will host a conference call on Thursday, November 12, 2026, at 4:30 p.m. Eastern Time to discuss its third-quarter 2026 results.
Why it matters — BEAT watchers may note the scheduled call as an opportunity to hear the company discuss its quarterly results.
HeartBeam announced positive results from a heart attack pilot study at TCT 2026, reporting that its patient-recorded 3D ECG was as accurate as a standard 12-lead ECG.
Why it matters — The study results provide an update on the reported performance of HeartBeam’s patient-recorded 3D ECG technology.
HeartBeam said it will present results from its ALIGN-ACS study on heart attack assessment at TCT 2026 on November 1, 2026.
Why it matters — The presentation will provide BEAT watchers with an update on the company's ALIGN-ACS study.
The HEADSTART-ACS study completed enrollment ahead of schedule. It is described as the largest heart attack detection study to date using HeartBeam technology.
Why it matters — The study's enrollment milestone is relevant to BEAT watchers following clinical evaluation of HeartBeam technology.
HeartBeam joined the European EXIT-CVD research consortium, which is focused on advancing at-home ECG monitoring for early detection of acute coronary syndrome in high-risk patients.
Why it matters — The consortium participation relates to HeartBeam’s work on at-home ECG monitoring and early detection of acute coronary syndrome.
The 3 Wall Street analysts covering HeartBeam, Inc. have a median 12-month price target of $3.5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering HeartBeam, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartBeam, Inc. 26 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, HeartBeam, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +725.3% from the last close, and Ticker Nerd's factor model ranks HeartBeam, Inc. 26 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HeartBeam, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
HeartBeam, Inc. returned -74.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
HeartBeam, Inc. is a medical technology company that develops cardiac diagnostic solutions for use both inside and outside clinical settings.
The most recent item we track (Business Wire, 3 Nov 2026): "HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time". HeartBeam announced it will host a conference call on Thursday, November 12, 2026, at 4:30 p.m. Eastern Time to discuss its third-quarter 2026 results.
HeartBeam, Inc. is a medical technology company that develops cardiac diagnostic solutions for use both inside and outside clinical settings. The company’s core offering is a portable, cable-free ECG platform designed to capture the heart’s electrical activity from three dimensions and synthesize it into a 12-lead ECG for physician review. Its products and software are aimed at helping clinicians detect and monitor arrhythmias and other cardiac conditions through remote and ambulatory workflows. HeartBeam’s current product portfolio includes a patient-held ECG device, a companion mobile application, physician software, and cloud-based analysis tools that support cardiac assessment and care coordination. Based in Santa Clara, California, HeartBeam operates in the healthcare technology market, with a focus on ambulatory cardiovascular diagnostics and telehealth-enabled cardiac monitoring.
CEO Mr. Robert P. Eno · 16 employees · United States · https://www.heartbeam.com
